AstraZeneca executives touted the benefits of further establishing themselves in Massachusetts’ biopharma “ecosystem” as the Big Pharma opened a new R&D center on Monday.
The 570,000-square-foot site, which comprises lab space and offices, claims a high-octane corner of Kendall Square in Cambridge, Mass., the beating heart of the Boston area biopharma scene. The 18-story building includes 10 floors of interconnecting laboratories, which the company has said will “allow a flow of seamless science enabled by cutting-edge technologies that integrate robotics, continuous automation and agentic AI.”
The site will house “nearly” 2,000 researchers and scientists who will be focused on developing drugs in areas like chronic obstructive pulmonary disease, obesity and metabolic disease, breast cancer and rare diseases, while “leveraging next-generation innovation like cell therapy and biologics,” an AstraZeneca spokesperson told Fierce.
Despite this wide-ranging research, cancer was the biggest topic of conversation at Monday’s ribbon-cutting ceremony, which Fierce attended.
“The day when we can cure many cancers is not far—even metastatic cancers,” AstraZeneca CEO Pascal Soriot said at the event.
“This is an exciting time to be in our industry,” added Soriot, who name-checked cell therapies and T cell engagers as areas of particular promise.
Soriot also called out the particulars of this new building for being on the bleeding edge of environmentally conscious development. The building is all-electric, running only on renewable energy, and utilizing a water recycling system to reduce waste.
Other AstraZeneca executives and elected officials who spoke at the ceremony all touted the unparalleled opportunity the area brings for collaboration across industry and academia. You don’t have to look any further than the block the new building sits on to see what they mean: the R&D center rubs shoulders with the Broad Institute of MIT and Harvard to its immediate right and Thermo Fisher Scientific's gene therapy manufacturing site to its left.
“As part of this ecosystem, we are now working alongside the scientific and research talent that is here in this special place—the world-class hospitals, the pioneering scientific institutions—that will allow us to achieve amazing things,” Sharon Barr, Ph.D., AstraZeneca’s head of biopharmaceuticals R&D, said at the opening.
The U.K.-based Big Pharma is no stranger to the Boston area, having already established an earlier outpost in Kendall Square and another in Boston’s Seaport neighborhood. In fact, the new R&D center is part of the pharma’s $1 billion commitment to the state, which is paired with a promise to increase the company’s workforce in Massachusetts by over 50% “in the coming years.”
Massachusetts Governor Maura Healey was there yesterday to affirm the mutual benefit of the state’s intellectual powerhouse as an asset to companies like AstraZeneca and the economic benefit those companies then bring to the region. Back in 2024, Healey signed into law the Mass Leads Act, a $4 billion move to bring in economic development, of which the latest AstraZeneca site is part.
“You know, I’m a little competitive,” the governor said, receiving warm laughter from the room. “It is imperative that we do all we can … to ensure that this area, this ecosystem—there's nothing like it in the world—remains strong and thriving.”
Where Big Pharma is placing its biggest bets is one of the hot topics being discussed at Fierce Biotech's high-impact event in London next month. Find out more information and register by clicking on the banner below:
